SoftOx Solutions AS (OSL:SOFTX)

Market Cap	292.37M
Revenue (ttm)	9.31M
Net Income (ttm)	-19.65M
Shares Out	2.24B
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,567,820
Average Volume	19,406,062
Open	0.1290
Previous Close	0.1095
Day's Range	0.1270 - 0.1475
52-Week Range	0.0100 - 0.1745
Beta	1.89
RSI	65.82
Earnings Date	Sep 17, 2025

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It is also developing antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norway...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2024, SoftOx Solutions AS's revenue was 7.91 million, an increase of 13.38% compared to the previous year's 6.98 million. Losses were -42.94 million, 8.86% more than in 2023.